Year over year, deal activity in the ABA sector has been climbing. M&A advisory firm Mertz Taggart reported that first-quarter 2025 transaction volume in the autism and intellectual/developmental disabilities space hit its highest mark since 2021, with 12 deals representing a 71% year-over-year increase. A PricewaterhouseCoopers analysis found 68 behavioral health deals totaling $1.2 billion in disclosed value between January and May of 2025 alone, with Q1 deal volume up 35% year over year. Capstone Partners’ October 2025 behavioral healthcare market update showed healthy year-over-year gains in deal activity, with strategic acquirers posting a 105% increase. The numbers arrive from firms with different methodologies and client bases, and they all point in the same direction.
The early data from 2025 pointed toward acceleration. “Autism M&A is booming because patient populations are growing,” Andre Ulloa, founder and managing director of M&A Healthcare Advisors, noted in a March 2025 analysis. “Five years ago, we had massive consolidation, and now mature platforms are bolting on acquisitions.” Kevin Taggart, managing partner at Mertz Taggart, described the competitive intensity around ABA deals as notably elevated, observing that one of the ABA companies his firm worked with in the first quarter received the highest number of offers for any deal the firm had handled since 2021. Insurance parity laws, the destigmatization of behavioral health, and sustained demand growth have continued driving both utilization and investor interest, even amid broader macroeconomic uncertainty.
The Consolidation Engine
The increase in M&A activity stems from a self-reinforcing cycle that many ABA providers know firsthand.
As in many healthcare subsectors, private equity participation in ABA has produced a wide range of outcomes, from high-growth success stories to complex restructurings. A study published in JAMA Pediatrics in January 2026 documented 574 PE-acquired autism service delivery sites across 42 states between 2015 and 2024, with nearly 80 percent of acquisitions occurring between 2018 and 2022. Private equity firms actively seek autism platforms with scalable infrastructure and strong payer relationships, companies whose operational backbone and clinical documentation systems can be replicated across new markets. PE has historically dominated deal activity in the autism space to a degree that exceeds its share in the broader behavioral health market, though 2025 has shown early signs of strategic buyers reclaiming a larger share of transactions.
Meanwhile, smaller, founder-led and mid-sized providers face structural pressures that make remaining independent increasingly challenging. Slow reimbursement from payers, surprise audits, onerous pre-authorization requirements, and a chronic shortage of Board Certified Behavior Analysts all squeeze margins from every direction. For these operators, the daily reality involves waiting on Medicaid payments that arrive weeks late, scrambling to hire and retain RBTs in a labor market where retail chains offer comparable wages with less emotional toll, and managing paperwork that multiplies with every new payer contract. Many respond by joining forces with one another, pooling resources to lower administrative burden, technology costs, and compliance demands. But that very consolidation makes them attractive acquisition targets in the eyes of those same private equity firms, reinforcing the cycle from both ends.
Following acquisition, organizations often undergo rapid operational change, and outcomes vary widely depending on strategy, execution, and market conditions. In some cases, pressure to scale quickly can strain onboarding, staffing, and clinical operations. A PE firm acquires a regional provider, layers in centralized back-office functions, and begins scouting for tuck-in acquisitions to expand the footprint. When this goes well, it can bring real efficiencies. When it doesn’t, the consequences tend to arrive quickly.
Turnover increases as onboarding processes get rushed to meet growth targets. Caseloads spike, and clinical quality can suffer if growth outpaces operational capacity. The last cycle provides several instructive examples: CARD, once valued at $600 million under Blackstone’s ownership, filed for Chapter 11 bankruptcy in 2023. Major layoffs swept through organizations like Elemy. Many of the sector’s most visible setbacks were financial rather than clinical in nature, though the two categories have a way of converging when an organization is under enough pressure.
Conversely, well-capitalized platforms have enabled significant expansion into underserved regions, investment in technology, and professionalization of operations in ways a founder-led practice could never afford. The best-run platforms bring consistency to training, build compliance infrastructure, and deploy data systems that can improve outcomes. And when public markets turn volatile, as they have in recent years, privately held behavioral health companies tend to attract additional investor interest as a comparatively stable alternative.
Private equity is already embedded in autism services, and the capital is not going anywhere. The ongoing question across the sector is whether it can be deployed in ways that balance financial objectives with sustainable clinical outcomes.
Who Sold?
Several recent transactions illustrate both the health of the current market and the range of outcomes it produces.
InBloom Autism Services. The most closely watched exit of the past year belongs to InBloom, which Webster Equity Partners acquired in 2018 and sold in a deal completed near the end of 2025. According to Axios, Elysium Management, the family office of Leon Black, co-founder and former CEO of Apollo Global Management, acquired InBloom for $75 million at a multiple of approximately 15x EBITDA. Calex Partners served as the exclusive financial advisor. The seven-year hold period ran well beyond the typical three-to-five-year window for PE-backed autism transactions, likely reflecting both the pandemic’s disruption and the broader deal-volume slowdown that sharply reduced behavioral health transaction volume from 2021 peak levels. InBloom had expanded to more than two dozen locations through de novo growth, and in early 2026 announced the opening of three new clinics in Connecticut. The buyer profile is notable: a family office rather than a traditional PE fund, with a longer time horizon and different return expectations than a typical institutional acquirer.
A Change in Trajectory (ACT). ACT, a California-based ABA provider that serves Los Angeles County and the Central Valley with more than 400 therapists and staff, sold to the Pine Street Group in July 2025. Pine Street, which already holds ABA portfolio companies including ABA Plus and Achieve Beyond’s California assets, has been quietly assembling a Southern California-focused autism platform through targeted tuck-in acquisitions. The deal fits a familiar template: a regional provider with strong clinical relationships and local payer contracts gets absorbed into a growing platform that provides operational infrastructure in exchange for geographic reach. Southern California, with its high population density, relatively favorable reimbursement environment, and deep pool of clinical talent, has long been among the most contested markets in ABA.
Child’s Play Therapy Services. In January 2026, Child’s Play, a Lafayette, California-based occupational therapy practice founded by Christina Gallo in 2009, partnered with Proficio Therapy Services. Child’s Play retains full clinical independence while supporting Proficio’s broader growth strategy. The deal expands Proficio’s network to twelve clinics across California and Utah, with four additional openings planned this year. While this transaction sits slightly outside the core ABA lane (Child’s Play specializes in pediatric OT with speech therapy support), it reflects a broader trend toward multidisciplinary pediatric therapy platforms that bundle ABA, OT, and speech under one operational umbrella. Families navigating a child’s autism diagnosis often need multiple therapies simultaneously, and providers that can offer all of them under a single roof, with a single intake process and a single billing relationship, have found that the model resonates with both families and payers.
Broadstep Behavioral Health. In an adjacent transaction, Broadstep Behavioral Health sold some of its community-based operations to ncgCare, a Richmond, Virginia-based behavioral healthcare network. Intrepid Investment Bankers served as the exclusive financial advisor. Broadstep, a Bain Capital Double Impact portfolio company, provides care to children and adults with intellectual and developmental disabilities and co-occurring mental health conditions across multiple states. The sold programs, based in North Carolina, were absorbed into Carolina Outreach, ncgCare’s North Carolina partner organization. While not an ABA deal, the transaction involves many of the same dynamics at play in autism services: PE hold periods stretching past their typical windows, operational complexity across state lines, and the pull of larger platforms. Broadstep had been on an aggressive acquisition streak in 2021, purchasing regional providers to expand its multi-state footprint, before going quiet. Terms were not disclosed.
Center for Social Dynamics / Behavior Change Institute. In a deal announced February 19, Center for Social Dynamics acquired Behavior Change Institute, a New Mexico-based ABA and diagnostic provider recognized for its clinical expertise, research leadership, and commitment to equitable access to care in underserved communities. CSD, backed by Goldman Sachs Alternatives (which acquired the company from NMS Capital in December 2024), operates across multiple states and delivers ABA therapy through in-person and virtual models. “This is far more than a geographic expansion,” CSD CEO Kelly Bozarth said in a statement. “It’s a values-driven union built around impact.” BCI co-founder and CEO Kathleen Karimi echoed the framing, saying the partnership is “about expanding critical access with integrity, and advancing this mission faster than either organization could do on its own.” Welham Advisory, led by Rajat Bangar, served as BCI’s advisor on the transaction. The deal reflects the ongoing appetite among scaled, well-capitalized platforms to acquire regional providers with strong clinical reputations and deep local payer relationships, particularly in markets where access to autism services remains limited. Terms were not disclosed.
LEARN Behavioral / Cornerstone Autism Center. Also announced February 19, LEARN Behavioral completed the integration and rebrand of Cornerstone Autism Center, an Indiana-based provider with locations in Avon, Greenwood, and West Lafayette. The three sites now operate under the Behavior Analysis Center for Autism (BACA) brand, expanding BACA’s Indiana footprint to nine learning centers. LEARN, backed by Gryphon Investors since 2019, is one of the larger scaled platforms in ABA, operating more than 100 learning centers across 23 states and delivering both center-based and in-home services. The Cornerstone integration is a tuck-in that fits the pattern of PE-backed platforms absorbing regional providers and consolidating them under a unified brand and operational infrastructure. Terms were not disclosed.
Who’s Coming to Market?
If the recent deals show what is behind us, a handful of companies now positioning for sale offer a preview of what 2026 will look like. The pipeline is unusually concentrated, with several large, well-known platforms approaching the market simultaneously.
Butterfly Effects. The Deerfield Beach, Florida-based provider is long overdue for a trade by any conventional PE timeline. Moran Capital Partners has held the company for approximately eleven years, nearly three times the median hold period for PE-backed autism transactions. Butterfly Effects has grown from ten states to twelve, offering both in-home and center-based care models, and opened six new centers in 2025. The company generates roughly $20 million in EBITDA, according to sources familiar with the matter who spoke with Acuity Media Network. The company is rumored to be represented by Triple Tree, the Minneapolis-based healthcare investment bank and Capital One subsidiary.
360 Behavioral Health. 360 Behavioral Health is reportedly positioning for a sale with an estimated $30 million in EBITDA, according to sources who spoke with Acuity Media Network. The company is represented by Calex Partners, the same advisory firm that handled the InBloom exit. Like many providers in the space, 360 underwent operational restructuring during the pandemic-era disruptions that forced much of the industry to adapt, but the company emerged from that period in a strong position. For potential buyers, 360 presents a scaled platform with stabilized operations and the kind of infrastructure that has become increasingly valuable as the market rewards operational depth over raw growth.
Mosaic Pediatric Therapy. Charlotte, North Carolina-based Mosaic provides ABA services across North Carolina and Virginia with approximately $26 million in annual revenue. The company is returning to market after a previous sale process was pulled, a sequence not unusual in the space, particularly during the deal-volume trough of 2023 and 2024 when several processes were quietly shelved. Mosaic is represented by Harris Williams.
Bierman Autism Centers. Westfield, Indiana-based Bierman Autism Centers is also reportedly exploring a sale, according to sources cited by Axios Pro. The company has engaged Cain Brothers to advise on the process. Founded in 2006, Bierman operates a network of center-based clinics focused on early intensive behavioral intervention for young children with autism and has expanded across multiple states in recent years. While financial details have not been publicly disclosed, the company’s footprint and focus on center-based care position it as a mid-market platform asset in a sector where buyers have increasingly favored providers with standardized clinical models and purpose-built treatment centers. The process is believed to be in its early stages, according to Axios Pro.
What the Pipeline Signals
The volume of platforms positioning for sale reflects several converging forces.
Many PE firms that invested in ABA between 2017 and 2020 are now well past their typical hold windows, and the firms approaching the end of investment cycles are increasingly seeking liquidity events. Industry advisors describe an environment where PE firms need to deploy aging dry powder and return capital to limited partners after several slow quarters. The sector’s fundamentals remain strong, but the current market is also shaped by the structural mechanics of private equity: the need to demonstrate realized returns and justify the next fundraise.
Well-run ABA platforms of a certain scale continue to command EBITDA multiples in the mid-to-high teens, according to industry sources, a range that has held relatively steady even as due diligence processes have matured and buyer sophistication has increased. Dan Beuerlein, a managing director at Brentwood Capital Advisors, has noted that autism platforms currently command the highest valuations within behavioral health, a function of the segment’s strong demand dynamics, outpatient focus, and fragmented provider landscape. But the gap between strong and weak performers is widening. Buyers are more skeptical of inflated margins, and more attuned to the operational realities (workforce shortages, payer complexity, state-by-state regulatory variation) that can erode a seemingly attractive thesis. At a recent BHASe Summit panel on M&A lessons, transaction advisors and founders described an investment committee environment that has little patience for aspirational pro formas or thin geographic footprints across many states, favoring instead proven unit economics, de novo repeatability, and clinical depth in core markets. Industry advisors note that some sellers continue to market providers with profit margins of 50% to 60%, when a well-run, compliant organization typically operates closer to 10% to 20%.
Due diligence in the sector has also evolved considerably since 2018 and 2019, when capital poured into behavioral health at historic volumes. The firms evaluating ABA companies today routinely examine authorization rates, cancellation patterns, BCBA-to-client ratios, and the granular economics of state Medicaid programs. A provider billing $200 an hour in one state may be billing $85 in the next, and the difference has everything to do with policy and nothing to do with quality. The result is a market that increasingly distinguishes between operational depth and surface-level growth.
For smaller providers, the options are narrowing: grow independently, pursue partnerships, or participate in consolidation. The deal pipeline building for 2026 suggests the market’s pull toward scale is accelerating. Whether this next wave of transactions produces better outcomes than the last will depend on whether disciplined capital deployment, sustainable growth strategies, and durable partnerships between investors and clinicians prove to be the exception or the norm. The deals, in either case, are already underway.
